On March 31, 2026, Lieutenant Governor Dan Patrick and House Speaker Dustin Burrows announced that the State of Texas would proceed with its own ibogaine clinical trial program, using the $50 million the state legislature had allocated the previous year. The announcement was unusual for two reasons. First, no U.S. state had ever directly funded clinical research into a Schedule I substance at this scale. Second, the announcement came after every pharmaceutical company that submitted a proposal failed to meet the state's requirements — leaving Texas to run the trial itself, through a consortium of public universities.
The program now has a name: IMPACT — Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma. It is the most significant ibogaine clinical trial in the United States to date, and one of the few large-scale, publicly funded psychedelic research programs in American history.
For patients, families, and clinicians watching this space, IMPACT represents both a milestone and a clarification. It is a milestone because federal and state momentum on ibogaine has now produced a concrete research vehicle. It is a clarification because the realistic timeline to FDA approval — even with this trial fully funded and underway — is still years away. For anyone seeking ibogaine treatment today, the practical answer remains what it has been for over a decade: medically supervised treatment in Mexico.
This article explains what IMPACT is, how it came together, what it will actually study, why FDA approval is still realistically 2029 or later, and what it means for patients who cannot wait.
What Is the IMPACT Ibogaine Clinical Trial?
IMPACT is a two-year, multicenter clinical research program led by UTHealth Houston in collaboration with The University of Texas Medical Branch at Galveston (UTMB Health). It is funded by a $50 million grant from the Texas Health and Human Services Commission, authorized by Senate Bill 2308 — signed into law by Governor Greg Abbott in June 2025.
The consortium is unusually broad. Participating institutions include:
- UTHealth Houston (consortium lead)
- The University of Texas Medical Branch at Galveston (UTMB Health) (co-lead)
- The University of Texas at Austin
- The University of Texas Health Science Center at San Antonio
- The University of Texas at Tyler
- The University of Texas Rio Grande Valley
- Texas Tech University
- Texas Tech University Health Sciences Center El Paso
- Texas A&M University
- The University of North Texas Health Science Center
- Baylor College of Medicine
- JPS Health Network (Dallas)
The clinical scope is divided across two main research tracks. UTHealth Houston and its partners will focus on ibogaine treatment for addiction and associated conditions — particularly opioid use disorder. UT Austin and Baylor College of Medicine will concentrate on traumatic brain injury (TBI), with a specific focus on veterans. PTSD research will run across multiple participating institutions.
The program's stated goal is to generate the safety and efficacy data necessary to support an eventual FDA-approved ibogaine treatment in the United States. That means designing trials that meet FDA standards for evidence — randomized, controlled, with rigorous cardiac monitoring and validated outcome measures.
How IMPACT Came Together: The SB 2308 Story
The path from legislation to launch was not smooth. Understanding why matters, because it tells you something important about the current state of ibogaine research in the United States.
Senate Bill 2308, passed by the Texas Legislature in 2025, allocated $50 million in state matching funds specifically for an ibogaine clinical trial. The bill's structure was straightforward in intent: a public university would manage the trial in partnership with a pharmaceutical company and a teaching hospital. The pharma partner would provide the regulatory expertise and capital match required to push a Schedule I compound through FDA review.
The conditions for that pharma partner were demanding. Any qualifying company had to provide a credible plan to obtain FDA approval, establish a corporate presence in Texas, match the state's $50 million investment dollar-for-dollar, and commit 20 percent of future drug revenue back to Texas.
Multiple companies submitted proposals. None met the standards. The state could not find a pharmaceutical partner willing to accept those conditions for a compound carrying ibogaine's regulatory and cardiac safety profile.
In March 2026, rather than abandoning the program, Patrick and Burrows announced that Texas would proceed without a pharma partner — using the consortium of universities to manage the trial directly. This shift required some legislative and legal reconciliation, since SB 2308 as written specified a public-private partnership structure. The fix is being worked out concurrently with trial design.
For ibogaine advocates, the pharma rejection was both frustrating and clarifying. It confirmed something the research community already knew: bringing a Schedule I compound with known cardiac risks through FDA approval is a project that the pharmaceutical industry is, at present, not eager to undertake. The economics, the regulatory complexity, and the cardiac safety burden are real obstacles. Texas's decision to proceed anyway is significant precisely because it represents a public commitment that the private market would not match.
The Federal Layer: Trump's April 2026 Executive Order
Eighteen days after Patrick and Burrows announced that Texas would run the trial itself, President Trump signed Executive Order 14306 — Accelerating Medical Treatments for Serious Mental Illness — directly referencing ibogaine twice in the order's text.
The executive order does not legalize ibogaine. It does not change its Schedule I classification. What it does is meaningful in a different way: it directs the FDA to fast-track review of psychedelic compounds that have received Breakthrough Therapy designation, allocates $50 million through ARPA-H to match state-level research investment (Texas being the most obvious beneficiary), creates a Right to Try pathway for eligible patients with serious conditions, and instructs the DEA to begin rescheduling reviews once Phase 3 trials succeed.
The order also expands VA participation in psychedelic therapy clinical trials. For veterans — who remain the most visible constituency in the ibogaine conversation — that expansion is significant. The Department of Veterans Affairs is now participating in at least five psychedelic therapy trials across multiple states.
Together, SB 2308 and the executive order form the most coherent federal-state pipeline for psychedelic research in American history. IMPACT sits at the center of it. For a full breakdown of what the order does and does not do, see our coverage of Trump's Ibogaine Executive Order: What the 2026 White House Announcement Means for Veterans and Treatment in Mexico.
What IMPACT Will Actually Study
IMPACT's research scope reflects what ibogaine appears to do clinically — which is unusual for a single compound. Most pharmacological agents target one condition or one neurological pathway. Ibogaine, by contrast, has shown effects across opioid dependence, PTSD, depression, anxiety, and traumatic brain injury, often within a single treatment session.
Addiction and opioid use disorder. UTHealth Houston's portion of the trial will focus on ibogaine's effect on substance use disorders, particularly opioid dependence. This is the use case with the longest research history — University of Miami trials in the late 1990s and early 2000s suggested significant reductions in withdrawal severity and improved abstinence rates following a single treatment session. The Texas trials will be the first to test these findings under modern FDA-compliant protocols.
Traumatic brain injury. UT Austin and Baylor College of Medicine will lead the TBI research, building on the foundational 2024 Stanford study published in Nature Medicine. That study, which followed 30 special operations veterans, reported significant improvements in cognitive function, PTSD symptoms, and disability scores following a single ibogaine session combined with intravenous magnesium. IMPACT's TBI track will examine whether those findings replicate in a larger, more diverse population — and whether the effect is sustained at longer follow-up intervals.
PTSD and behavioral health. Multiple consortium institutions will contribute to PTSD-focused research. This track is particularly relevant to veteran populations, where treatment-resistant PTSD remains one of the most persistent unmet needs in American medicine.
The trial's two-year duration covers initial design and Phase 1/early Phase 2 work. It is not, on its own, sufficient to support an FDA New Drug Application. It is the beginning of a longer pipeline.
The Realistic Timeline: When Will Ibogaine Be Legal in the United States?
This is the question that matters most for patients, and it is the question most often answered with optimism that the regulatory facts do not support.
Here is what the realistic timeline looks like, based on current trial scope and FDA process requirements.
2026–2027. IMPACT trial design finalized. Phase 1 safety studies begin. DemeRx — a U.S. biopharmaceutical company with FDA Investigational New Drug authorization for an ibogaine derivative (noribogaine, an active metabolite) — continues its independent Phase 2/3 work on opioid use disorder. Federal Right to Try pathway becomes operational for eligible patients with serious conditions, though access remains narrow.
2027–2028. Phase 2 data begins to accumulate. State pilot programs in Texas, Mississippi, and elsewhere generate real-world evidence. Pressure mounts for DEA rescheduling, but rescheduling cannot proceed until clinical data supports it.
2028–2029. Phase 3 trials complete (if everything proceeds on schedule, which clinical trials rarely do). New Drug Applications submitted to FDA. Review typically takes 12 months for standard pathway, less under priority review.
2029–2030. Earliest realistic FDA approval window, contingent on successful trial outcomes and acceptable safety profile. DEA rescheduling proceeds in parallel.
This is the optimistic version. The cautionary example is MDMA-assisted therapy, which completed Phase 3 trials and was still rejected by the FDA in 2024 over trial design concerns. Psychedelic medicine is moving faster than it ever has in the United States, but it is still moving at the pace of clinical research — not at the pace of headlines.
For patients suffering now, the implications are direct: FDA-approved ibogaine treatment in the United States is, at minimum, three to four years away. For many, it will be longer.
The Cardiac Question: Why FDA Approval Is Harder for Ibogaine
One reason no pharmaceutical company would partner with Texas on the original SB 2308 terms is the cardiac risk profile of ibogaine. This is the regulatory issue that any honest discussion of ibogaine clinical trials has to address.
Ibogaine prolongs the QT interval in the heart. In patients with pre-existing cardiac conditions, electrolyte imbalances, or certain concurrent medications, prolonged QT can lead to torsades de pointes — a potentially fatal arrhythmia. There have been deaths at unscreened, unsupervised facilities. The FDA, the Stanford research team, and every credible ibogaine clinic agrees on this: ibogaine is not a treatment that can be administered without proper cardiac screening, continuous monitoring, and medical oversight.
The 2024 Stanford trial managed this risk by administering intravenous magnesium alongside ibogaine, which appears to counteract the QT-prolonging effect. Thirty veterans completed treatment with zero serious cardiac adverse events. The IMPACT trials will follow similar protocols — full cardiac workups before treatment, IV magnesium during, continuous monitoring throughout.
What this means in regulatory terms is that ibogaine cannot be approved as a take-home medication. Any FDA-approved ibogaine treatment will almost certainly be administered only in qualified clinical settings, with cardiac screening and monitoring as a condition of administration. That is not a minor design consideration — it shapes the entire commercial pathway, and it is one reason the pharmaceutical industry has been slow to engage.
The clinics in Mexico that operate seriously already follow these protocols. They have, in effect, been running the safety model that any FDA-approved version of this treatment will eventually adopt.
What This Means for Patients Considering Ibogaine Treatment Now
The temptation, reading IMPACT coverage, is to wait. If the trial is running, if the federal government is now involved, if FDA approval is on the horizon — surely the right move is to hold off until ibogaine is legally available in the United States.
For patients with conditions that can wait three to seven years, that may be reasonable. For most of the people actually seeking ibogaine treatment, it is not.
Treatment-resistant PTSD, severe opioid dependence, and traumatic brain injury are conditions that progress. Untreated, they cause measurable damage — to careers, relationships, and in too many cases, lives. The veterans funded by VETS (Veterans Exploring Treatment Solutions) — over 1,200 to date, with nine in ten applicants turned away — are not waiting because they cannot afford to wait. Marcus Capone, the former Navy SEAL who founded VETS with his wife Amber, has been explicit that the nonprofit exists precisely because the regulatory timeline is incompatible with the timeline of human suffering.
Ibogaine treatment is currently available — legally and under medical supervision — in Mexico. It has been for over two decades. The clinics that operate seriously in Tijuana, Cancún, Puerto Vallarta, and Baja California follow the same cardiac safety protocols that the IMPACT trial will use: pre-treatment 12-lead ECG, comprehensive medical and medication screening, IV magnesium administration, continuous cardiac monitoring, and physician oversight throughout the session.
These clinics are not a workaround. They are, for the moment, the only medically supervised ibogaine treatment available to American patients. The IMPACT trial will eventually expand that landscape. It does not change it today. If you are ready to explore your options, our ibogaine clinic directory for Mexico is a starting point for identifying providers who operate with the medical seriousness this treatment demands.
What to Watch Next
For anyone tracking ibogaine clinical trials in the United States, several developments over the next 18 months will shape the trajectory.
IMPACT trial design publication. The full study protocols are still being finalized. Publication of the trial design will reveal which ibogaine formulation (ibogaine HCl, noribogaine, or a derivative), which dosing strategy, and which outcome measures will be used. This will determine how readily IMPACT findings can be compared to existing research from Mexico and elsewhere.
DemeRx Phase 3 progress. DemeRx remains the leading private-sector candidate for an FDA-approved ibogaine-class compound. Their noribogaine program, which has Investigational New Drug status, is the only ibogaine-derivative program currently on track for a New Drug Application submission before 2030.
Right to Try implementation. The federal Right to Try pathway created by Trump's executive order has not yet seen its first ibogaine application. How the FDA and DEA actually operationalize this pathway will determine whether it provides meaningful access for individual patients before full approval.
Additional state legislation. Mississippi's HB 314 (passed March 2026), Indiana's expanded therapeutic research fund, Colorado's HB 26-1325, and Vermont's SB 77 are all in various stages of implementation. The state-level pattern is now bipartisan and momentum is real.
VA trial participation. The Department of Veterans Affairs is participating in at least five psychedelic therapy trials. Expanding VA involvement specifically in ibogaine research — as the executive order directs — would represent the federal government's most direct endorsement of ibogaine's clinical value.
Key Facts: The IMPACT Ibogaine Trial at a Glance
Trial name: Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma (IMPACT)
Lead institutions: UTHealth Houston and UTMB Health (Galveston)
Funding: $50 million from Texas Health and Human Services Commission (via SB 2308)
Federal layer: Trump executive order, Accelerating Medical Treatments for Serious Mental Illness, April 18, 2026
Trial duration: Two years (initial phase)
Research tracks: Addiction and opioid use disorder (UTHealth Houston lead); traumatic brain injury (UT Austin and Baylor); PTSD (multi-institutional)
Realistic earliest FDA approval window: 2029–2030
Ibogaine's current U.S. status: Schedule I controlled substance, unchanged by executive order
Currently legal medically supervised treatment: Mexico (Tijuana, Cancún, Puerto Vallarta, Baja California, and elsewhere)
Further Reading
- White House: Accelerating Medical Treatments for Serious Mental Illness (Executive Order, April 18, 2026)
- Texas Senate Bill 2308 (signed June 2025)
- Stanford / Nature Medicine ibogaine study (Cherian et al., February 2024) — our full summary
- Trump's Ibogaine Executive Order: What the 2026 White House Announcement Means for Veterans and Treatment in Mexico
- In Waves and War: The Netflix Documentary Bringing Ibogaine Therapy for Veterans Into the Mainstream
- Our ibogaine clinic directory for Mexico
This article is for informational and research purposes only. Ibogaine is a Schedule I controlled substance in the United States. Nothing here constitutes medical or legal advice. Anyone considering ibogaine therapy should consult qualified medical professionals and ensure treatment is conducted in a fully medically supervised setting.